Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Discovery | 7 | 2024 | 170 | 1.230 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2024 | 523 | 1.030 |
Why?
|
| Polypharmacology | 3 | 2020 | 4 | 0.850 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2023 | 23 | 0.840 |
Why?
|
| Gold | 1 | 2022 | 48 | 0.810 |
Why?
|
| Spermatozoa | 1 | 2023 | 231 | 0.740 |
Why?
|
| Mebendazole | 1 | 2016 | 7 | 0.550 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2016 | 8 | 0.550 |
Why?
|
| Small Molecule Libraries | 4 | 2024 | 118 | 0.500 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 1661 | 0.480 |
Why?
|
| ras Proteins | 1 | 2016 | 136 | 0.480 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2023 | 148 | 0.480 |
Why?
|
| Signal Transduction | 4 | 2024 | 4489 | 0.480 |
Why?
|
| Models, Molecular | 2 | 2021 | 1070 | 0.460 |
Why?
|
| Contraceptive Agents, Male | 2 | 2024 | 23 | 0.420 |
Why?
|
| Pancreatic Neoplasms | 3 | 2023 | 673 | 0.360 |
Why?
|
| RNA, Long Noncoding | 2 | 2023 | 208 | 0.330 |
Why?
|
| DNA | 5 | 2024 | 1591 | 0.290 |
Why?
|
| Quantitative Structure-Activity Relationship | 2 | 2016 | 15 | 0.270 |
Why?
|
| Ligands | 3 | 2016 | 530 | 0.270 |
Why?
|
| Molecular Docking Simulation | 2 | 2016 | 112 | 0.260 |
Why?
|
| Activin Receptors, Type I | 1 | 2024 | 33 | 0.240 |
Why?
|
| Glioblastoma | 2 | 2020 | 334 | 0.240 |
Why?
|
| Enzyme Activation | 2 | 2022 | 617 | 0.230 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2024 | 59 | 0.220 |
Why?
|
| Contraception | 1 | 2024 | 59 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2023 | 171 | 0.220 |
Why?
|
| RNA, Small Nucleolar | 1 | 2023 | 13 | 0.220 |
Why?
|
| beta-Lactamase Inhibitors | 1 | 2023 | 55 | 0.210 |
Why?
|
| Lipolysis | 1 | 2023 | 82 | 0.210 |
Why?
|
| Kynurenine | 1 | 2023 | 21 | 0.210 |
Why?
|
| Smad Proteins | 1 | 2023 | 43 | 0.210 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2022 | 100 | 0.200 |
Why?
|
| Phenylalanine Hydroxylase | 1 | 2021 | 11 | 0.190 |
Why?
|
| Phenylketonurias | 1 | 2021 | 12 | 0.190 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 183 | 0.190 |
Why?
|
| Phenylalanine | 1 | 2021 | 120 | 0.190 |
Why?
|
| Humans | 23 | 2024 | 123033 | 0.190 |
Why?
|
| Protease Inhibitors | 1 | 2021 | 94 | 0.180 |
Why?
|
| Muscular Atrophy | 1 | 2021 | 74 | 0.180 |
Why?
|
| Oxygen | 1 | 2024 | 547 | 0.180 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2020 | 68 | 0.170 |
Why?
|
| Endometrium | 1 | 2023 | 277 | 0.170 |
Why?
|
| ARNTL Transcription Factors | 1 | 2020 | 38 | 0.170 |
Why?
|
| CLOCK Proteins | 1 | 2020 | 28 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 304 | 0.170 |
Why?
|
| Pinocytosis | 1 | 2019 | 7 | 0.160 |
Why?
|
| Syndecan-1 | 1 | 2019 | 7 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 714 | 0.160 |
Why?
|
| Uterus | 1 | 2023 | 594 | 0.150 |
Why?
|
| Glycoproteins | 1 | 2020 | 369 | 0.140 |
Why?
|
| Structure-Activity Relationship | 3 | 2024 | 567 | 0.140 |
Why?
|
| Wnt-5a Protein | 1 | 2016 | 21 | 0.140 |
Why?
|
| Binding Sites | 2 | 2018 | 1291 | 0.140 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 75 | 0.140 |
Why?
|
| ErbB Receptors | 1 | 2018 | 284 | 0.130 |
Why?
|
| Dasatinib | 1 | 2016 | 41 | 0.130 |
Why?
|
| Drug Design | 1 | 2017 | 146 | 0.130 |
Why?
|
| Nuclear Proteins | 1 | 2022 | 1265 | 0.130 |
Why?
|
| Computational Biology | 2 | 2020 | 798 | 0.120 |
Why?
|
| Exons | 1 | 2018 | 794 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2021 | 827 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 604 | 0.120 |
Why?
|
| Pharmacology | 1 | 2014 | 10 | 0.120 |
Why?
|
| Receptor, ErbB-2 | 1 | 2018 | 494 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 332 | 0.120 |
Why?
|
| Mice | 8 | 2024 | 17512 | 0.120 |
Why?
|
| Animals | 10 | 2024 | 33767 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 2388 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2014 | 356 | 0.100 |
Why?
|
| Molecular Structure | 2 | 2024 | 285 | 0.100 |
Why?
|
| Software | 1 | 2016 | 676 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2023 | 3274 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2826 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 1590 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2023 | 1872 | 0.080 |
Why?
|
| Male | 6 | 2024 | 60066 | 0.080 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 530 | 0.070 |
Why?
|
| Protein Binding | 2 | 2021 | 1741 | 0.070 |
Why?
|
| Activin Receptors, Type II | 1 | 2024 | 30 | 0.060 |
Why?
|
| Blood-Testis Barrier | 1 | 2024 | 11 | 0.060 |
Why?
|
| Receptors, Eph Family | 1 | 2024 | 21 | 0.060 |
Why?
|
| Receptor, EphA2 | 1 | 2024 | 26 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2023 | 2307 | 0.060 |
Why?
|
| Carbon | 1 | 2024 | 91 | 0.060 |
Why?
|
| beta-Lactams | 1 | 2023 | 50 | 0.060 |
Why?
|
| Rejuvenation | 1 | 2023 | 10 | 0.050 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2023 | 15 | 0.050 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2023 | 16 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2024 | 444 | 0.050 |
Why?
|
| Penicillins | 1 | 2023 | 154 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2023 | 56 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2023 | 91 | 0.050 |
Why?
|
| Protein Stability | 1 | 2023 | 164 | 0.050 |
Why?
|
| Adipocytes | 1 | 2023 | 158 | 0.050 |
Why?
|
| Gene Library | 1 | 2023 | 220 | 0.050 |
Why?
|
| Epithelium | 1 | 2023 | 361 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2023 | 151 | 0.050 |
Why?
|
| Testis | 1 | 2024 | 405 | 0.050 |
Why?
|
| Peptide Initiation Factors | 1 | 2021 | 30 | 0.050 |
Why?
|
| Acetylgalactosamine | 1 | 2021 | 10 | 0.050 |
Why?
|
| beta-Lactamases | 1 | 2023 | 192 | 0.050 |
Why?
|
| Molecular Conformation | 1 | 2021 | 100 | 0.050 |
Why?
|
| Neoplasms | 1 | 2016 | 2758 | 0.050 |
Why?
|
| Protein Domains | 1 | 2022 | 234 | 0.050 |
Why?
|
| Endometriosis | 1 | 2024 | 185 | 0.050 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2021 | 97 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2023 | 320 | 0.050 |
Why?
|
| Nucleic Acid Conformation | 1 | 2021 | 184 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2023 | 777 | 0.040 |
Why?
|
| Genetic Engineering | 1 | 2021 | 161 | 0.040 |
Why?
|
| Cell Movement | 1 | 2024 | 831 | 0.040 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2020 | 41 | 0.040 |
Why?
|
| Methylation | 1 | 2020 | 226 | 0.040 |
Why?
|
| RNA Stability | 1 | 2020 | 85 | 0.040 |
Why?
|
| Cell Self Renewal | 1 | 2020 | 41 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2021 | 225 | 0.040 |
Why?
|
| ADP-Ribosylation Factors | 1 | 2019 | 4 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 179 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 4275 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 202 | 0.040 |
Why?
|
| Microglia | 1 | 2020 | 96 | 0.040 |
Why?
|
| Homeostasis | 1 | 2023 | 682 | 0.040 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2019 | 92 | 0.040 |
Why?
|
| Arginine | 1 | 2020 | 303 | 0.040 |
Why?
|
| Female | 5 | 2024 | 65497 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 156 | 0.040 |
Why?
|
| Virus Replication | 1 | 2021 | 602 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 353 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1682 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 294 | 0.040 |
Why?
|
| Mutagenesis, Insertional | 1 | 2018 | 147 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 877 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2018 | 230 | 0.040 |
Why?
|
| Quinazolines | 1 | 2018 | 175 | 0.030 |
Why?
|
| Drug Repositioning | 1 | 2017 | 22 | 0.030 |
Why?
|
| Drug Industry | 1 | 2017 | 45 | 0.030 |
Why?
|
| PAX6 Transcription Factor | 1 | 2016 | 37 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 216 | 0.030 |
Why?
|
| Apoptosis | 1 | 2023 | 1781 | 0.030 |
Why?
|
| Epigenomics | 1 | 2016 | 162 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2021 | 3042 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2020 | 810 | 0.030 |
Why?
|
| Neural Stem Cells | 1 | 2016 | 126 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2023 | 1909 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2021 | 937 | 0.030 |
Why?
|
| Databases, Chemical | 1 | 2014 | 2 | 0.030 |
Why?
|
| Diet | 1 | 2021 | 1126 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 254 | 0.030 |
Why?
|
| Liver | 1 | 2021 | 1736 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 488 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2020 | 2809 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2016 | 545 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2021 | 3718 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2016 | 527 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 2022 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 2771 | 0.030 |
Why?
|
| Obesity | 1 | 2023 | 2227 | 0.020 |
Why?
|
| Internet | 1 | 2014 | 378 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 4354 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1592 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2016 | 2585 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 5771 | 0.010 |
Why?
|
| Aged | 1 | 2020 | 19082 | 0.010 |
Why?
|
| Middle Aged | 1 | 2020 | 25980 | 0.010 |
Why?
|